Department of Veterinary Science, University of Turin, Grugliasco, Italy.
Department of Veterinary Science, University of Turin, Grugliasco, Italy.
Res Vet Sci. 2021 May;136:351-359. doi: 10.1016/j.rvsc.2021.03.010. Epub 2021 Mar 13.
To compare the analgesic effects of oral administration of cimicoxib and tramadol over a 30 day period following Tibial Plateau Leveling Osteotomy and partial menisectomy in dogs.
Randomized, double blinded, prospective clinical trial.
42 adult client-owned dogs with unilateral cranial cruciate ligament disease and partial meniscal tears.
Dogs were allocated into 2 treatment groups (cimicoxib or tramadol). Weight bearing while standing, thigh circumference, flexion and extension range of motions, wound classification, adverse effects, Visual Analogue Scale (VAS), Glasgow Composite Measure Pain Scale (CMPS-SF) and Helsinki Chronic Pain Index (HCPI) questionnaire and limb function by means of pressure platform gait analysis were recorded before surgery and at several time points after surgery for 30 days. Outcome measures were compared at each time point among groups.
A significant improvement in two objective measures of gait of the cimicoxib group: the vertical impulse on day 1 and day 20 and the peak vertical force on day 20 were significantly improved when compared to the tramadol group. However, no difference was seen for the VI or PVF of dogs on the other days compared. In addiction there was no difference in the weight bearing while standing, thigh circumference, wound classification, adverse effects, VAS, CMPS-SF and HCPI. We did not observe a difference in the number of adverse effects measured in this study with the exception of hock edaema.
A significant difference was not found in long-term postoperative analgesia provided by cimicoxib or tramadol in dogs undergoing TPLO when subjective parameters (with the exception of knee joint range of motion) were evaluated, but use of the force plate analysis revealed a significant difference between groups at T20 for both PVF and VI. The use of cimicoxib improved the limb function and ROM and reduced the occurrence of hock edema, in the first 20 days after surgery, without any additional side effects, compared to tramadol. Thus, the use of cimicoxib should be preferred to tramadol alone in clinical cases similar to the ones included in this study.
比较口服昔布昔康和曲马多在犬胫骨平台平整化截骨术和部分半月板切除术后 30 天的镇痛效果。
随机、双盲、前瞻性临床试验。
42 只患有单侧十字韧带疾病和部分半月板撕裂的成年患犬。
将犬分为 2 个治疗组（昔布昔康或曲马多）。术前及术后 30 天内，分别在站立负重、大腿围度、屈伸活动范围、伤口分级、不良反应、视觉模拟评分（VAS）、格拉斯哥复合疼痛量表（CMPS-SF）和赫尔辛基慢性疼痛指数（HCPI）问卷以及通过压力平台步态分析评估的肢体功能等方面进行记录。比较各组在各时间点的结果。
昔布昔康组在 2 个步态客观指标上有明显改善：第 1 天和第 20 天的垂直冲击和第 20 天的峰值垂直力明显改善，与曲马多组相比。然而，其他日子的狗的 VI 或 PVF 没有差异。此外，站立负重、大腿围度、伤口分级、不良反应、VAS、CMPS-SF 和 HCPI 均无差异。除后肢肿胀外，本研究中测量的不良反应数量无差异。
在接受 TPLO 的犬中，长期使用昔布昔康或曲马多治疗后，在主观参数（膝关节活动范围除外）方面未发现明显差异，但使用力板分析在 T20 时发现两组在 PVF 和 VI 方面存在显著差异。与曲马多相比，在术后前 20 天，使用昔布昔康可改善患肢功能和 ROM，减少后肢肿胀的发生，且无其他不良反应。因此，与单独使用曲马多相比，在类似于本研究中包含的病例中，应优先使用昔布昔康。
